When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes
American Journal of Cardiovascular Drugs · 2026-09 · 26 (5) · 603-619
DOI: 10.1007/s40256-026-00817-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 23.07.2026. Verfasst von Zeyad Elariny und 13 weiteren Autor:innen. Beteiligte Einrichtung: Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Blood Pressure, Antihypertensive Agents, Hypertension, Benzazepines. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Lorundrostat has emerged as a promising therapy for uncontrolled and/or resistant hypertension, with multiple systematic reviews and meta-analyses (SRMAs) evaluating its blood pressure effects and hyperkalemia risk. Despite drawing from identical trials, reported effect sizes varied markedly, warranting an umbrella review.
Methods
Conducted per the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD420261358169), this umbrella review included SRMAs of lorundrostat in adults with uncontrolled hypertension. Pooled estimates for systolic blood pressure (SBP), diastolic blood pressure (DBP), and hyperkalemia risk were extracted and compared. Methodological quality was assessed using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2), and primary study overlap was quantified via corrected covered area (CCA).
Results
Ten SRMAs were included; seven focused exclusively on lorundrostat, all showing complete overlap (CCA = 100%). Despite this, substantial variability in pooled estimates was observed. Office SBP reductions ranged from − 7.35 to − 13.55 mmHg (the 95% confidence interval [CI] ranged between − 28.57 and 1.47), 24-h ambulatory SBP ranged from − 5.65 to − 7.45 mmHg (the 95% CI ranged between − 13.60 and 2.31), and DBP reductions were relatively consistent at approximately − 3 to − 4 mmHg, but with the 95% CI ranging between − 7.93 and 0.61. Variability stemmed primarily from differences in dose handling, outcome definitions, and analytical approaches. Lorundrostat was consistently associated with elevated hyperkalemia risk (RR 3.19–11.63), though severity was rarely stratified. Methodological quality was predominantly low to critically low.
Conclusion
Lorundrostat produces a modest blood pressure reduction in uncontrolled hypertension. Current evidence is constrained by methodological heterogeneity, limited long-term data, and inadequate safety reporting. Standardized analytical approaches and greater transparency are essential. The proposed effect size concordance index (ECI) may complement overlap metrics by capturing agreement in effect magnitude and precision; however, further validation is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
- Faculty of Medicine, Benha National University, Obour City, Egypt.
- Lecturer of Pharmacology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt. omnia.azmy@kasralainy.edu.eg.
Zitieren
APA
Elariny, Z., Salem, O., Salaheldin, M. A., Ahmed, A., Rabie, F., Sayed, M. M., Harish, M., Ali, M., Eliwa, S. A., Elshorbagy, M., ElHarouni, S., Abdelmeguid, A., Ahmed, R., & Nabeh, O. A. (2026). When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes. American Journal of Cardiovascular Drugs, 26(5), 603-619. https://doi.org/10.1007/s40256-026-00817-5
Vancouver
Elariny Z, Salem O, Salaheldin MA, Ahmed A, Rabie F, Sayed MM, et al. When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes. American Journal of Cardiovascular Drugs. 2026;26(5):603-619. doi:10.1007/s40256-026-00817-5
BibTeX
@article{Elariny2026,
author = {Elariny, Zeyad and Salem, Omar and Salaheldin, Mohamad Ashraf and Ahmed, Adham and Rabie, Farida and Sayed, Maryam Mohamed and Harish, Mohamed and Ali, Mohamed and Eliwa, Selim Ahmed and Elshorbagy, Mohammad and ElHarouni, Sara and Abdelmeguid, Ahmed and Ahmed, Retaj and Nabeh, Omnia Azmy},
title = {When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes},
journal = {American Journal of Cardiovascular Drugs},
year = {2026},
volume = {26},
number = {5},
pages = {603--619},
doi = {10.1007/s40256-026-00817-5}
}
EUVIMED